Efficacy and Safety of Aflibercept in Combination With Chemotherapy Beyond Second-Line Therapy in Metastatic Colorectal Carcinoma Patients: An AGEO Multicenter Study-Reference-Cited by-同舟云学术

Efficacy and Safety of Aflibercept in Combination With Chemotherapy Beyond Second-Line Therapy in Metastatic Colorectal Carcinoma Patients: An AGEO Multicenter Study

Published:2020-03 Issue:1 Volume:19 Page:39-47.e5
ISSN:1533-0028
Container-title:Clinical Colorectal Cancer
language:en
Short-container-title:Clinical Colorectal Cancer

Author:

Auvray Marie,Tougeron David,Auclin Edouard,Moulin Valérie,Artru Pascal,Hautefeuille Vincent,Hammel Pascal,Lecomte Thierry,Locher Christophe,Sickersen Gaëlle,Coriat Romain,Lecaille Cédric,Vernerey Dewi,Taieb Julien,Pernot Simon

Publisher

Elsevier BV

Subject

Gastroenterology,Oncology

Reference25 articles.

1. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer;Hurwitz;N Engl J Med,2004

2. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study;Saltz;J Clin Oncol,2008

3. Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial;Passardi;Ann Oncol,2015

4. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial;Cunningham;Lancet Oncol,2013

5. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial;Heinemann;Lancet Oncol,2014

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A systemic review and meta-analysis of Aflibercept plus FOLFIRI regimen as a second-line treatment for metastatic colorectal cancer: A PRISMA compliant pooled analysis of randomized controlled trials and single arm studies to assess efficacy and safety;Critical Reviews in Oncology/Hematology;2023-08

2. Safety and efficacy review of aflibercept for the treatment of metastatic colorectal cancer;Expert Opinion on Drug Safety;2022-01-05

3. Aflibercept Plus FOLFIRI as Second-Line Treatment for Metastatic Colorectal Cancer: A Single-Institution Real-Life Experience;Cancers;2021-07-31

4. Are All Anti-Angiogenic Drugs the Same in the Treatment of Second-Line Metastatic Colorectal Cancer? Expert Opinion on Clinical Practice;Frontiers in Oncology;2021-05-10

5. Forkhead-box A3 (FOXA3) Represses Cancer Stemness and Partially Potentiates Chemosensitivity by Targeting Metastasis-Associated in Colon Cancer 1 (MACC1) Signaling Pathway in Colorectal Cancer Cells;Current Cancer Drug Targets;2021-04-26